The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Abstract
Patients with type 2 diabetes mellitus or the metabolic syndrome have a unique dyslipidemia characterized by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol, in particular HDL(2)-C. Treatment of the dyslipidemia associated with these disorders should focus on correcting the abnormal lipoprotein levels as well as LDL and HDL heterogeneity. Statins and fibrates are useful for treating elevated LDL in patients with and without diabetes or the metabolic syndrome. In addition, thiazolidinediones or niacin in combination with a statin show promise for correcting defects in LDL and HDL heterogeneity. The ultimate goal of treatment in this patient population is to prevent the development and progression of coronary artery disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mild hypertriglyceridemia, typically seen in treated type 2 diabetes, is probably related to the presence of central obesity and insulin resistance (83).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [83]
In the citing paper
“Unfortunately, hypertriglyceridemia is often not effectively treated, leading to a significant unmet therapeutic need in an increasingly obese population (Brunzell and Ayyobi, 2003).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Brunzell and Ayyobi, 2003
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Banting lecture 1988. Role of insulin resistance in human disease.
Reaven, G. (1988) · Diabetes · doi:10.2337/diabetes.37.12.1595 · Cited by 3,801
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.6.1595 · Cited by 3,133
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B., Sinha, M. K., Boyko, E. J., Retzlaff, B. M., Knopp, R. H., Brunzell, J. D., & Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1074-z · Cited by 1,483
Self-citationAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Fujioka, S., Matsuzawa, Y., Tokunaga, K., & Tarui, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90063-1 · Cited by 1,205
Franz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.148 · Cited by 1,165
Self-citationGoldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986
Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 849
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 792
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Sniderman, A. D., Shapiro, S., Marpole, D. G. F., Skinner, B., Teng, B., & Kwiterovich, P. O. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.1.604 · Cited by 632
Enzi, G., Gasparo, M., Biondetti, P., Fiore, D., Semisa, M., & Zurlo, F. (1986) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/44.6.739 · Cited by 547
Griffin, B. A., Freeman, D. J., Tait, G. W., Thomson, J., Caslake, M. J., Packard, C. J., & Shepherd, J. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90129-5 · Cited by 525
Ashwell, M., Cole, T. J., & Dixon, A. K. (1985) · BMJ · doi:10.1136/bmj.290.6483.1692 · Cited by 401
McNamara, J. R., Campos, H., Ordovás, J. M., Peterson, J., Wilson, P. W. F., & Schaefer, E. J. (1987) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.7.5.483 · Cited by 383
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 331
Tchernof, A., Lamarche, B., Prud'homme, D., Nadeau, A., Moorjani, S., Labrie, F., Lupien, P. J., & Després, J.-P. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.629 · Cited by 323
Kelly, I. E., Han, T. S., Walsh, K., & Lean, M. E. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.288 · Cited by 314
Nieves, D. J., Cnop, M., Retzlaff, B., Walden, C. E., Brunzell, J. D., Knopp, R. H., & Kahn, S. E. (2003) · Diabetes · doi:10.2337/diabetes.52.1.172 · Cited by 281
Self-citationZambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Self-citationAustin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., Brunzell, J. D., & Motulsky, A. G. (2000) · Circulation · doi:10.1161/01.cir.101.24.2777 · Cited by 255
Self-citationDesprés, J., Moorjani, S., Ferland, M., Tremblay, A., Lupien, P. J., Nadeau, A., Pinault, S., Thériault, G., & Bouchard, C. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.2.203 · Cited by 254
Effect of hepatic lipase on LDL in normal men and those with coronary artery disease.
Zambon, A., Austin, M. A., Brown, B. G., Hokanson, J. E., & Brunzell, J. D. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.2.147 · Cited by 249
Self-citationApolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
Packard, C. J., Demant, T., Stewart, J., Bedford, D. K., CASLAKE, M. J., Schwertfeger, G., Bedynek, A., Shepherd, J., & Seidel, D. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32065-4 · Cited by 240
Freed, M. I., Ratner, R. E., Marcovina, S. M., Kreider, M. S., Biswas, N., Cohen, B. R., & Brunzell, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02659-0 · Cited by 238
Self-citationInheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis.
Austin, M. A., King, M., VRANIZAN, K. M., Newman, B. M., & Krauss, R. M. (1988) · PubMed · Cited by 234
Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients
Carey, D., Cowin, G., Galloway, G. J., Jones, N. P., Richards, J. C., Biswas, N., & Doddrell, D. M. (2002) · Obesity Research · doi:10.1038/oby.2002.137 · Cited by 210
Quantitative and Qualitative Lipoprotein Abnormalities in Diabetes Mellitus
Taskinen, M. (1992) · Diabetes · doi:10.2337/diab.41.2.s12 · Cited by 174
Effect of Weight Loss with Reduction of Intra-Abdominal Fat on Lipid Metabolism in Older Men
Purnell, J. Q. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.977 · Cited by 161
Self-citationLDL particle size distribution. Results from the Framingham Offspring Study.
Campos, H., Blijlevens, E., McNamara, J. R., Ordovas, J. M., Posner, B. M., Wilson, P. W., Castelli, W. P., & Schaefer, E. J. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.12.1410 · Cited by 158
Dyslipidemia of the metabolic syndrome
Ruotolo, G., & Howard, B. V. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0113-6 · Cited by 155
Abnormal Body Fat Distribution Detected by Computed Tomography in Diabetic Men
Shuman, W. P., Morris, L., Leonetti, D. L., WAHL, P. W., Moceri, V. M., Moss, A. A., & Fujimoto, W. Y. (1986) · Investigative Radiology · doi:10.1097/00004424-198606000-00007 · Cited by 148
Dyslipidemia of central obesity and insulin resistance.
Brunzell, J. D., & Hokanson, J. E. (1999) · PubMed · Cited by 135
Self-citationCarr, M. C., Hokanson, J. E., Zambon, A., Deeb, S. S., Barrett, P. H. R., Purnell, J. Q., & Brunzell, J. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7586 · Cited by 120
Self-citationMcKenney, J. M., McCormick, L. S., Schaefer, E. J., Black, D. M., & Watkins, M. L. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01639-3 · Cited by 120
Zambon, A., Deeb, S. S., Brown, B. G., Hokanson, J. E., & Brunzell, J. D. (2001) · Circulation · doi:10.1161/01.cir.103.6.792 · Cited by 114
Self-citationThe visceral adiposity syndrome in Japanese-American men.
Fujimoto, W., Abbate, S. L., Kahn, S. E., Hokansno, J. E., & Brunzell, J. (1994) · Obesity Research · doi:10.1002/j.1550-8528.1994.tb00076.x · Cited by 111
Self-citationYale, J., Valiquett, T. R., Ghazzi, M. N., Owens-Grillo, J. K., Whitcomb, R. W., Foyt, H. L., & for the Troglitazone Triple-Therapy Study Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-9_part_1-200105010-00010 · Cited by 102
Nakamura, T., Funahashi, T., Yamashita, S., Nishida, M., Nishida, Y., Takahashi, M., Hotta, K., Kuriyama, H., Kihara, S., Ohuchi, N., et al. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00319-9 · Cited by 101
Obesity: Mechanisms and Clinical Management
Eckel, R. H. (2003) · Cited by 66
Features of Syndrome X in First-Degree Relatives of NIDDM Patients
Stewart, M. W., Humphriss, D. B., Berrish, T. S., Barriocanal, L. A., Trajano, L. R., Alberti, K. G. M. M., & WALKER, M. C. (1995) · Diabetes Care · doi:10.2337/diacare.18.7.1020 · Cited by 65
New developments in the use of niacin for treatment of hyperlipidemia
Crouse, J. R. (1996) · Coronary Artery Disease · doi:10.1097/00019501-199604000-00009 · Cited by 62
McNeely, M. J., Edwards, K. L., Marcovina, S. M., Brunzell, J. D., Motulsky, A. G., & Austin, M. A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00528-7 · Cited by 54
Self-citationPouliot, M. C., Després, J., Nadeau, A., Tremblay, A., Moorjani, S., Lupien, P. J., Thériault, G., & Bouchard, C. (1990) · PubMed · Cited by 42
Hepatic Lipase as a Focal Point for the Development and Treatment of Coronary Artery Disease
Zambon, A., Brown, B. G., Deeb, S. S., & Brunzell, J. D. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.34107 · Cited by 29
Self-citationMultiple Risk Factors in Cardiovascular Disease
Achari, A. (1995) · Medical science symposia series · doi:10.1007/978-94-011-0039-7 · Cited by 25
Fujimoto, W. Y., Leonetti, D. L., Newell‐Morris, L. L., Shuman, W. P., & WAHL, P. W. (1991) · PubMed · Cited by 24
Multiple risk factors in cardiovascular disease
Licata, A. A. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90076-q · Cited by 4
Research works printed but not linked: 3
- Austin, 1988, Inheritance of low-density lipoprotein subclass patterns, Am J Hum Genet, 43, 838
- Greene, 2000, A Diabetes Outcome Progression Trial (ADOPT) of long-term rosiglitazone, metformin, and glyburide monotherapy in drug-naïve patients, Diabetes, 49, A343
- Home, 2002, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD), Diabetes, 51, A487
Cited by
Sorted by citations
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010
“A 2-h post 75-g oral glucose challenge be performed in PCOS women with a BMI greater than 30 kg/m2, or alternatively in lean PCOS women with advanced age ( 40 yr), personal history of gestational diabetes, or family history of T2DM (44, 93).”
ResultInfluentialEvaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
“the presence of central obesity and insulin resistance (83).”
Self-citationHavel, P. J. (2005) · Nutrition Reviews · doi:10.1111/j.1753-4887.2005.tb00132.x · Cited by 607
“High triglyceride levels are an independent risk factor for coronary heart disease.(57,58) This understanding is based largely on evidence metaanalyses of population-based studies.”
BackgroundHansel, B., Giral, P., Nobécourt, E., Chantepie, S., Bruckert, É., Chapman, M. J., & Kontush, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0305 · Cited by 476
Ginsberg, H. N., & MacCallum, P. R. (2009) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00044.x · Cited by 331
Metadata
- Authors
- Brunzell, J. D., & Ayyobi, A. F.
- Affiliations
- University of Washington (US)
- Corresponding author
- Ayyobi, Amir F
- ORCID
- Brunzell, John D
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 115
- Issue
- 8
- Pages
- 24-28
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2030751874
- Cited by
- 155
- References
- 63
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 12 · 2013: 10 · 2012: 12
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- dyslipidemia, metabolic syndrome, type 2 diabetes, hypertriglyceridemia, apolipoprotein B, small dense LDL, HDL cholesterol, HDL2-C, lipoprotein heterogeneity, statins, fibrates, thiazolidinediones, nicotinic acid, coronary heart disease prevention
- MeSH terms
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Lipase, Cholesterol, HDL, Cholesterol, LDL, Receptor, Insulin, Risk Factors, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
